Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 522-530

  Aggarwal, Rahul R ^a   Ryan, Charles J ^a   Chan, June M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deprivation therapy; Castration resistant; Insulin resistance; Insulin like growth factor; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CIXUTUMUMAB; DOCETAXEL; FIGITUMUMAB; GANITUMAB; MITOXANTRONE; NORDIHYDROGUAREACETIC ACID; SOMATOMEDIN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DISEASE COURSE; FEBRILE NEUTROPENIA; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAXIMUM TOLERATED DOSE; MORTALITY; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; UPREGULATION;

ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

EID: 84874102233     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.05.001     Document Type: Review

References (61)

1. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979-3983.
2. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006, 106:581-588.
3. Dockery F., Bulpitt C.J., Agarwal S., et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003, 104:195-201.
4. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261-4267.
5. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599-603.
6. Smith M.R., Lee H., Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-1308.
7. Keating N.L., O'Malley J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4455.
8. Albanes D., Weinstein S.J., Wright M.E., et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009, 101:1272-1279.
9. Whittemore A.S., Kolonel L.N., Wu A.H., et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995, 87:652-661.
10. Hsing A.W., Gao Y.T., Chua S., et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst 2003, 95:67-71.
11. Schuurman A.G., Goldbohm R.A., Dorant E., et al. Anthropometry in relation to prostate cancer risk in The Netherlands Cohort Study. Am J Epidemiol 2000, 151:541-549.
12. Hsing A.W., Deng J., Sesterhenn I.A., et al. Body size and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2000, 9:1335-1341.
13. Giovannucci E., Liu Y., Platz E.A., et al. Risk factors for prostate cancer incidence and progression in the health professionals follow up study. Int J Cancer 2007, 121:1571-1578.
14. Hammarsten J., Hogstedt B. Clinical, hemodynamic, anthropometric, metabolic, and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Pressure 2004, 13:47-55.
15. Lehrer S., Diamond E.J., Stagger S., et al. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002, 50:1-3.
16. Bassett W.W., Cooperberg M.R., Sadetsky N., et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Journal of Urology 2005, 66:1060-1065.
17. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004, 22:439-445.
18. Gong Z., Agalliu I., Lin D.W., et al. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007, 109:1192-1202.
19. Jayachandran J., Aronson W.J., Terris M.K., et al. Obesity and positive surgical margins by anatomic location after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. BJU Int 2008, 102:964-968.
20. Ma J., Haojie L., Giovannucci E., et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008, 9:1039-1047.
21. Hammarsten J., Hogstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005, 41:2887-2895.
22. Flanagan J., Gray P.K., Hahn N., et al. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 2011, 22:801-807.
23. Halabi S., Ou S., Vogelzang N.J., et al. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 2007, 110:1478-1484.
24. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nature Reviews Cancer 2004, 4:505-518.
25. Devi G., Doo-Hyun Y., Rosenfeld R.G., et al. Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. Endocrinology 2000, 141:4171-4179.
26. Andress D.L., Birnbaum R.S. Human osteoblast-derived insulin-like growth factor (IGF-I) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF-I action. J Biol Chem 1992, 267:467-472.
27. Lang C.H., Vary T.C., Frost R.A. Acute in vivo elevation in IGFBP-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology 2003, 144:3922-3933.
28. Yee D., Jackson J.G., Kozelsky T.W., et al. Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Diff 1994, 5:73-77.
29. Yu J., Iwashita M., Kudo Y., et al. Phosphorylated insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1 stimulates IGF-I-induced amino acid uptake by cultured trophoblast cells. Growth Hormone IGF Res 1998, 8:65-70.
30. Moses A.C., Young S.C., Morrow L.A., et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996, 45:91.
31. Rajpathak S.N., Gunter M.J., Wylie-Rosett J., et al. The role of insulin-like growth factor-1 and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 2009, 25:3-12.
32. Luo J., Murphy L.J. Differential expression of the insulin-like growth factor binding proteins in spontaneously diabetic rats. J Mol Endocrinol 1992, 8:155-163.
33. Kalme T., Seppala M., Qiao Q., et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab 2005, 90:1550-1556.
34. Lemne C., Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome-a study in borderline hypertension. Blood Pressure 1998, 7:88-95.
35. Rajpathak S.N., McGinn A.P., Strickler H.D., et al. Insulin-like growth factor (IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Hormone IGF Res 2008, 18:166-173.
36. Heald A.H., Siddals K.W., Fraser W., et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002, 51:2629-2636.
37. Gibson J.M., Westwood M., Young R.J., et al. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996, 81:860-863.
38. Roddam A.W., Allen N.E., Appleby P., et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Internal Med 2008, 149:461-471.
39. Cohen P., Peehl D.M., Graves H.C.B., et al. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994, 142:407-415.
40. Chan J.M., Meir J.S., Ma J., et al. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002, 94:1099-1106.
41. Rowlands M, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int J Cancer 124:2416-29.
42. Nickerson T., Chang F., Lorimer D., et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001, 61:6276-6280.
43. Hellawell G.O., Turner G.D.H., Davies D.R., et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002, 62:2942-2950.
44. Krueckl S.L., Sikes R.A., Edlund N.M., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004, 64:8620-8629.
45. Burfeind P., Chernicky C.L., Rininsland F., et al. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 1996, 93:7263-7268.
46. Goya M., Miyamoto S., Nagai K., et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004, 64:6252-6258.
47. Krueckl S.L., Sikes R.A., Edlund N.M., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004, 64:8620-8629.
48. Bubendorf L., Kolmer M., Kononen J., et al. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999, 91:1758-1764.
49. Thrasher B., Tennant M., Twomey P., et al. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: Clinical correlations. J Urol 1996, 155:999-1003.
50. Kiyama S., Morrison K., Zellweger T., et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003, 63:3575-3584.
51. Figueroa J., De Raad S., Tadlock L., et al. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998, 159:1379-1383.
52. Miyake H., Pollak M., Gleave M.E. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000, 60:3058-3064.
53. Xu C., Graf L.F., Fazli L., et al. Regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate 2007, 67:1621-1629.
54. Ryan C.J., Hagg C.M., Simko J., et al. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007, 25:134-140.
55. Higano CS, Alumkal JJ, Ryan CJ, et al. A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results. Proceedings of the ASCO Genitourinary Cancers Symposium, March 2010, San Francisco, CA. [Abstract].
56. Attard G, Fong PC, Molife R, et al. Phase I trial involving the pharmacodynamic (PD) study of circulating tumor cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer. Proceedings of the ASCO Annual Meeting, June 2006, Atlanta, GA. [Abstract].
57. Ryan C.J., Harzstark A.H., Rosenberg J., et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJUI 2008, 101:436-439.
58. Ryan C.J., Zavodovskaya M., Youngren J.F., et al. Inhibitory effects of nordihydroguareacetic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. The Prostate 2008, 68:1232-1240.
59. Tolcher A.W., Sarantopoulos J., Patnaik A., et al. Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1. J Clin Oncol 2009, 27:5800-5807.
60. He X.X., Tu S.M., Lee M.H., et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011 March 17, [Epub ahead of print].
61. Smith M.R., Manola J., Kaufman D.S., et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004, 101:1569-1574.